Literature DB >> 2668442

Correlation between apolipoprotein A-IV and triglyceride concentrations in human sera.

L Lagrost1, P Gambert, S Meunier, P Morgado, J Desgres, P d'Athis, C Lallemant.   

Abstract

Apolipoprotein A-IV concentration was measured by a newly developed competitive enzyme immunoassay in sera from fasted human subjects (n = 105) whose triglyceride concentrations ranged from 20 to 474 mg/dl (total cholesterol below 260 mg/dl) and in which chylomicrons could not be detected. Mean (+/- SD) apolipoprotein A-IV concentration was 13.0 +/- 2.6 mg/dl in sera with triglyceride levels ranging from 20 to 100 mg/dl, 16.9 +/- 3.7 mg/dl in sera with triglyceride levels ranging from 101 to 250 mg/dl, and 22.7 +/- 6.7 mg/dl in sera with triglyceride levels ranging from 251 to 474 mg/dl. The differences among the three groups were highly significant (P less than 0.001). Moreover, variations of apolipoprotein A-IV concentrations according to the triglyceride levels were noted within the normo-triglyceridemic population. Apolipoprotein A-IV concentration was 12.8 +/- 2.1 mg/dl for triglyceride levels ranging from 20 to 75 mg/dl and 16.4 +/- 3.8 mg/dl for triglyceride levels ranging from 76 to 150 mg/dl (P less than 0.01). In the entire population that was studied there was a significant linear correlation (r = 0.61, P less than 0.001) between the concentrations of serum apolipoprotein A-IV and triglyceride. Although the hypothesis of an unknown factor independently influencing both very low density lipoproteins and apolipoprotein A-IV cannot be ruled out, and although no apolipoprotein A-IV was found in the triglyceride-rich lipoprotein fraction after separation by gel filtration, these data suggest that, in fasting subjects, the secretion of very low density lipoproteins could contribute to the plasma apolipoprotein A-IV level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2668442

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

1.  Prevalence and associations of the metabolic syndrome among patients prescribed clozapine.

Authors:  M Ahmed; I Hussain; S M O'Brien; B Dineen; D Griffin; C McDonald
Journal:  Ir J Med Sci       Date:  2008-05-07       Impact factor: 1.568

2.  Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.

Authors:  Thomas Gautier; David Masson; Miek C Jong; Jean-Paul Pais de Barros; Linda Duverneuil; Naig Le Guern; Valérie Deckert; Laure Dumont; Amandine Bataille; Zoulika Zak; Xian-Cheng Jiang; Louis M Havekes; Laurent Lagrost
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

3.  Plasma lipoproteins in cortical infarction versus transient ischaemic attacks: a case control study.

Authors:  M C Boutron; M Giroud; P Gras; P Gambert; C Lallemant; C Milan; E Essayagh; R Dumas
Journal:  J Neurol       Date:  1993       Impact factor: 4.849

4.  Altered regulation of apolipoprotein A-IV gene expression in the liver of the genetically obese Zucker rat.

Authors:  W Strobl; B Knerer; R Gratzl; K Arbeiter; Y C Lin-Lee; W Patsch
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

5.  Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior.

Authors:  K Aalto-Setälä; C L Bisgaier; A Ho; K A Kieft; M G Traber; H J Kayden; R Ramakrishnan; A Walsh; A D Essenburg; J L Breslow
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

6.  A genome-wide association meta-analysis on apolipoprotein A-IV concentrations.

Authors:  Claudia Lamina; Salome Friedel; Stefan Coassin; Rico Rueedi; Noha A Yousri; Ilkka Seppälä; Christian Gieger; Sebastian Schönherr; Lukas Forer; Gertraud Erhart; Barbara Kollerits; Pedro Marques-Vidal; Janina Ried; Gerard Waeber; Sven Bergmann; Doreen Dähnhardt; Andrea Stöckl; Stefan Kiechl; Olli T Raitakari; Mika Kähönen; Johann Willeit; Ludmilla Kedenko; Bernhard Paulweber; Annette Peters; Thomas Meitinger; Konstantin Strauch; Terho Lehtimäki; Steven C Hunt; Peter Vollenweider; Florian Kronenberg
Journal:  Hum Mol Genet       Date:  2016-07-12       Impact factor: 6.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.